The British National Formulary for Children is the unrivalled guidance on prescribing, dispensing and administering medicines to children.

BNF for Children is the only child-focused drug formulary in the world that is both independent, and has rigorous, accredited content creation processes. It is trusted by health professionals worldwide as their primary source for minimising medication errors in paediatrics.

SubscribeContent Updates
Features and Benefits icon

Speed and safety: Provides rapid reference to essential information on the selection of safe and effective medicines for individual patients

Features and Benefits icon

Evidence Grading: As part of NICE accreditation recommendations, BNFc content is now evidence graded to reflect the strength of evidence behind them, increasing transparency to support healthcare professionals with clinical decision making

Features and Benefits icon

Always up-to-date: The content is revalidated, revised, and updated on a monthly basis, making sure you access only the very latest prescribing knowledge

Features and Benefits icon

Worldwide credibility: The BNFc uses clinical evidence from a diverse range of sources and a network of experts, giving you the confidence to select medicines safely

900 +

drugs

7million +

page views

200 +

treatment summaries

360

Searches per hour

Publication Updates

10 Nov
British National Formulary for Children logo
BNF for Children November 2020 Update

This update contains 10 significant changes, 2 dose changes and 2 new monographs.

Significant Changes:

  • Bedaquiline in combination regimen for multiple-drug resistant pulmonary tuberculosis [AWMSG guidance].
  • Cannabidiol with clobazam for therapy of seizures associated with Dravet syndrome [SMC guidance].
  • Cannabidiol with clobazam for therapy of seizures associated with Lennox-Gastaut syndrome [SMC guidance].
  • Fentanyl transdermal patches for non-cancer pain: do not use in opioid-naive patients [MHRA/CHM advice].
  • Immunoglobulins: updated guidance on the use of varicella-zoster immunoglobulin in-line with Public Health England recommendations.
  • Insulins (all types): risk of cutaneous amyloidosis at injection site [MHRA/CHM advice] (advice in biphasic insulin aspart, biphasic insulin lispro, biphasic isophane insulin, insulin, insulin aspart, insulin degludec, insulin detemir, insulin glargine, insulin glulisine, insulin lispro, isophane insulin; see example in insulin).
  • Methotrexate once-weekly for autoimmune diseases: new measures to reduce risk of fatal overdose due to inadvertent daily instead of weekly dosing [MHRA/CHM advice].
  • Opioids: risk of dependence and addiction [MHRA/CHM advice] (advice in alfentanil, buprenorphine, co-codamol, codeine phosphate, co-phenotrope, diamorphine hydrochloride, dihydrocodeine tartrate, fentanyl, hydromorphone hydrochloride, methadone hydrochloride, morphine, oxycodone hydrochloride, pethidine hydrochloride, remifentanil, tapentadol, tramadol hydrochloride; see example in morphine).
  • Poisoning, emergency treatment: updated guidance on the management of paracetamol poisoning in-line with TOXBASE recommendations.
  • Varicella-zoster vaccine: updated guidance in-line with Public Health England recommendations.

Dose Changes:

  • Glycopyrronium bromide [oral dosing in children updated].
  • Mercaptamine [update to dosing for nephropathic cystinosis].

New Monographs:

  • Kaftrio® [tezacaftor with ivacaftor and elexacaftor].
  • Sirturo® [bedaquiline].

For further details on changes in the BNFC click on
https://www.medicinescomplete.com/#/content/bnfc/PHP107699?hspl=changes

13 Oct
British National Formulary for Children logo
BNF for Children October 2020 Update

This update contains 19 significant changes, 6 dose changes, 1 new monograph and 1 new preparation.

Significant Changes: 

  • Amisulpride: Clozapine and other antipsychotics: monitoring blood concentrations for toxicity [MHRA/CHM advice].
  • Aripiprazole: Clozapine and other antipsychotics: monitoring blood concentrations for toxicity [MHRA/CHM advice].
  • Belimumab as add-on therapy for active, autoantibody-positive systemic lupus erythematosus with a high degree of disease activity despite standard therapy [AWMSG guidance].
  • Bisacodyl: Stimulant laxatives (bisacodyl, senna and sennosides, sodium picosulfate) available over-the-counter: new measures to support safe use [MHRA/CHM advice].
  • Clozapine: Clozapine and other antipsychotics: monitoring blood concentrations for toxicity [MHRA/CHM advice].
  • Entrectinib for treating NTRK fusion-positive solid tumours [NICE guidance].
  • Hydroxycarbamide for the prevention of vaso-occlusive complications of sickle-cell disease in patients over 2 years of age [AWMSG guidance].
  • Hydroxycarbamide for the prevention of vaso-occlusive complications of sickle-cell disease in patients over 2 years of age [SMC guidance].
  • Immunisation schedule: updated National flu immunisation programme in-line with Public Health England recommendations.
  • Influenza: updated guidance on management.
  • Influenza vaccine: updated guidance in-line with Public Health England recommendations.
  • Isotretinoin (Roaccutane®▼): reminder of important risks and precautions [MHRA/CHM advice].
  • Olanzapine: Clozapine and other antipsychotics: monitoring blood concentrations for toxicity [MHRA/CHM advice].
  • Quetiapine: Clozapine and other antipsychotics: monitoring blood concentrations for toxicity [MHRA/CHM advice].
  • Risperidone: Clozapine and other antipsychotics: monitoring blood concentrations for toxicity [MHRA/CHM advice].
  • Senna: Stimulant laxatives (bisacodyl, senna and sennosides, sodium picosulfate) available over-the-counter: new measures to support safe use [MHRA/CHM advice].
  • Sodium picosulfate: Stimulant laxatives (bisacodyl, senna and sennosides, sodium picosulfate) available over-the-counter: new measures to support safe use [MHRA/CHM advice].
  • Sulpiride: Clozapine and other antipsychotics: monitoring blood concentrations for toxicity [MHRA/CHM advice].
  • Tick-borne encephalitis vaccine: updated guidance in-line with Public Health England recommendations.

Dose Changes:

  • Benlysta® (belimumab) [dosing in children added].
  • Gaviscon infant® (alginic acid) [update to dosing for management of gastro-oesophageal reflux disease].
  • Influenza vaccine [update to dosing for immunisation].
  • Isotretinoin [indication updated].
  • Oseltamivir [update to dosing for treatment and prevention of influenza].
  • Zanamivir [update to dosing for treatment of influenza].

New Monograph:

  • Rozlytrek® [entrectinib].

New Preparation: Trecondi® [treosulfan].

For further details on changes in the BNFC click on https://www.medicinescomplete.com/#/content/bnfc/PHP107699?hspl=changes 

 

08 Sep
British National Formulary for Children logo
BNF for Children September 2020 Update

This update contains 6 significant changes, 1 dose change and 2 new monographs.

Significant Changes:
• Amphotericin: name change to amphotericin B.
• Amphotericin B: Liposomal and lipid-complex formulations: name change to reduce medication errors [MHRA/CHM advice].
• Cytarabine: Liposomal and lipid-complex formulations: name change to reduce medication errors [MHRA/CHM advice].
• Daunorubicin: Liposomal and lipid-complex formulations: name change to reduce medication errors [MHRA/CHM advice].
• Doxorubicin hydrochloride: Liposomal and lipid-complex formulations: name change to reduce medication errors [MHRA/CHM advice].
• Flucytosine: Updated recommendations for the use in patients with dihydropyrimidine dehydrogenase (DPD) deficiency [MHRA/CHM advice].

Dose Change:
• Cefixime [update to dosing for uncomplicated gonorrhoea].

New Monographs:
• Cefazolin.
• Veklury® [remdesivir].

For further details on changes in the BNFC click on
https://www.medicinescomplete.com/#/content/bnfc/PHP107699?hspl=changes

 
11 Aug
British National Formulary for Children logo
BNF for Children August 2020 Update

This update contains 3 significant changes, 8 dose changes, and 1 deleted monograph.

Significant Changes:

  • Genital system infections, antibacterial therapy: updated guidance for the management of uncomplicated gonorrhoea.
  • Ketotifen for the symptomatic treatment of seasonal allergic conjunctivitis [AWMSG guidance].
  • Smallpox vaccine: updated guidance in-line with Public Health England recommendations.

Dose Changes:

  • Azithromycin [update to dosing for uncomplicated gonorrhoea].
  • Ceftriaxone [update to dosing for gonococcal infections].
  • Chloroquine [update to dosing for prophylaxis of malaria].
  •  Ciprofloxacin [update to dosing for gonococcal infections].
  • Doxycycline [update to dosing for prophylaxis of malaria].
  • Proguanil hydrochloride [update to age range for prophylaxis of malaria].
  • Solifenacin succinate [update to include child dosing].
  • Tipranavir [dose removed for child 2-11 years as oral solution formulation discontinued].

Deleted Monograph: Stavudine

For further details on changes in the BNFC click on
https://www.medicinescomplete.com/#/content/bnfc/PHP107699?hspl=changes

14 Jul
British National Formulary for Children logo
BNF for Children July 2020 Update

This update contains 6 significant changes.

Significant Changes:

  • Hyperthyroidism: updated guidance on management.
  • Hypothyroidism: updated guidance on management.
  • Larotrectinib for treating NTRK fusion-positive solid tumours [NICE guidance].
  • Rabies vaccine: updated guidance in-line with Public Health England recommendations.
  • Sodium valproate: Valproate Pregnancy Prevention Programme: temporary advice for management during coronavirus (COVID-19) [MHRA/CHM advice].
  • Valproic acid: Valproate Pregnancy Prevention Programme: temporary advice for management during coronavirus (COVID-19) [MHRA/CHM advice].

For further details on changes in the BNFC click on https://www.medicinescomplete.com/#/content/bnfc/PHP107699?hspl=changes

09 Jun
British National Formulary for Children logo
BNF for Children June 2020 Update

This update contains 5 significant changes, 4 dose changes and 5 new preparations.

Significant Changes:

  • Adrenaline/epinephrine auto-injectors (Emerade®): all strengths of auto-injector pens have been recalled from patients due to failure to activate. Healthcare professionals are advised to ensure that patients who have previously been prescribed an Emerade® 150, 300 or 500 microgram pen are supplied with a prescription for an alternative brand—see the MHRA website for full details [MHRA/CHM advice].
  • Hypoglycaemia: updated guidance on management.
  • Poisoning, emergency treatment: updated guidance on the management of beta-blockers poisoning in-line with TOXBASE recommendations.
  • Poisoning, emergency treatment: updated guidance on the management of paracetamol poisoning in-line with TOXBASE recommendations.
  • Skin infections, antibacterial therapy: updated guidance on management of impetigo.

Dose Changes:

  • Co-fluampicil [update to dosing information].
  • Qvar® (beclometasone dipropionate) [age-range extension].
  • Seretide 50 Evohaler® (fluticasone with salmeterol) [age-range extension].
  • Seretide 100 Accuhaler® (fluticasone with salmeterol) [age-range extension].

New Preparations:

  • Combisal® 25/50 [fluticasone with salmeterol].
  • Combisal® 25/125 [fluticasone with salmeterol].
  • Combisal® 25/250 [fluticasone with salmeterol].
  • Fusacomb 50/250 Easyhaler® [fluticasone with salmeterol].
  • Fusacomb 50/500 Easyhaler® [fluticasone with salmeterol].

 

For further details on changes in the BNFC click on https://www.medicinescomplete.com/#/content/bnfc/PHP107699?hspl=changes 

View more View all content updates